Tumor growth factor-b (TGF-b) signaling in cancer has been implicated in growth suppression of early lesions and enhancing tumor cell invasion and metastasis. However, the cellular mechanisms that determine this signaling output in individual tumors are still largely unknown. In endothelial cells, TGF-b signaling is modulated by the TGF-b coreceptor endoglin (CD105). Here we demonstrate that endoglin is expressed in a subset of invasive breast cancers and cell lines and is subject to epigenetic silencing by gene methylation. Endoglin downregulation in non-tumorigenic MCF10A breast cells leads to the formation of abnormal acini in 3D culture, but does not promote cell migration or transformation. In contrast, in the presence of activated ErbB2, endoglin downregulation in MCF10A cells leads to enhanced invasion into a 3D matrix. Consistent with these data, ectopic expression of endoglin in MDA-MB-231 cells blocks TGF-b-enhanced cell motility and invasion and reduces lung colonization in an in vivo metastasis model. Unlike endothelial cells, endoglin does not modulate Smadmediated TGF-b signaling in breast cells but attenuates the cytoskeletal remodeling to impair cell migration and invasion. Importantly, in a large cohort of invasive breast cancers, lack of endoglin expression in the tumor cell compartment correlates with ENG gene methylation and poor clinical outcome.
Introduction
The tumor growth factor-b (TGF-b) signaling pathway has an important role in all stages of breast cancer progression. It is well established that TGF-b has a dual function in acting both as a tumor suppressor in the early stage of malignant progression and to promote invasive and metastatic events in late stage carcinomas (Roberts and Wakefield, 2003; Massague, 2008) . TGF-b ligands act by binding to their cognate transmembrane serine/ threonine kinase receptors (Shi and Massague, 2003; Feng and Derynck, 2005) . This results in the activation of the canonical TGF-b pathway mediated by the phosphorylation of Smad proteins and their subsequent translocation to the nucleus where they promote the transcriptional regulation of TGF-b response genes. However, TGF-b can also signal through a range of other pathways (Moustakas and Heldin, 2005; Zhang, 2009 ) and these alternate pathways are particularly important in the pro-invasive responses to TGF-b in cancer (Bhowmick et al., 2001; Ozdamar et al., 2005) .
Endoglin (CD105) is a type I integral transmembrane glycoprotein that has predominantly been investigated in the vasculature where it is upregulated during angiogenesis (Bernabeu et al., 2007 (Bernabeu et al., , 2009 ). In endothelial cells, endoglin associates at the cell surface with the type I and type II TGF-b receptors and has a key role in modulating downstream signaling to the Smad transducer proteins (Guerrero-Esteo et al., 2002; Lebrin et al., 2004) . The importance of endoglin acting as a TGF-b co-receptor in these events is evidenced by the observation that mutations in either ENG or the type I receptor ALK1 give rise to the vascular disorder hereditary hemorrhagic telangiectasia (McAllister et al., 1994; Johnson et al., 1996) . From an initial demethylation screen, we identified ENG as a candidate gene for epigenetic regulation in breast cancer cell lines. Together with previous reports that endoglin can inhibit the migration of other epithelial tumors (Craft et al., 2007; Perez-Gomez et al., 2007) , we hypothesized that expression of endoglin might function to suppress breast cancer progression. To address this we investigated the functional role of endoglin in both in vitro and in vivo models, its impact on the TGF-b signaling pathway and the prognostic impact and regulation of endoglin expression in a large cohort of invasive breast cancers.
Results

Downregulation of endoglin expression enhances breast cancer cell invasion
A panel of cell lines was subject to immunoblotting and quantitative real-time PCR (qPCR). Endoglin mRNA and protein expression was readily detected in the nontumorigenic breast cell line MCF10A, in a subset of the cancer cell lines (MDA-MB-468, SKBR3, T47D) and in the recently re-classified melanoma line MDA-MB-435 ( Figure 1a ). This expression was 2.5-5-fold lower than found in the cultured endothelial cells (Supplementary Figure 1) . No endoglin expression was detected in MCF7, Cal51, MDA-MB-231, MDA-MB-453, HCC1954 or BT474 cells. Reverse transcription-PCR analysis revealed that in the endoglin-positive cell lines the predominant expression was of the long-endoglin isoform with little or no expression of the short-endoglin isoform detected (data not shown).
To explore a potential role for endoglin as a breast cancer suppressor, we initiated this study with the nontumorigenic MCF10A cell line. MCF10A cells when grown on a thick layer of Matrigel form epithelial acini (3D culture model), and this system has been used extensively to identify pathways that can perturb the normal breast architecture (Debnath and Brugge, 2005) . MCF10A cells were stably infected with five individual endoglin lentiviral small hairpin RNAs (shRNAs) (shEng1-5) targeting different regions of the ENG gene or with control shRNA (shCont) (Figure 1b) . Substantial knockdown was observed with shEng1 and shEng5 but not with shEng2. The shEng2 and shCont cell lines expressed similar levels of endoglin as the parental line and hence were used as two independent controls. In this 3D culture model, shCont and shEng2 cells were indistinguishable from the parental MCF10A cells and formed single acini that contained a hollow lumen surrounded by a polarized layer of epithelial cells with their Golgi orientated inwards (Figure 1c ). In contrast, the endoglin-knockdown lines (shEng1 and shEng5) produced abnormally shaped acini in which the outer layer of cells was not fully polarized and the lumena were incompletely cleared. Nonetheless, these shEng1 and shEng5 acini, still growth arrested, did not invade into the Matrigel and were no larger than control structures indicating that the loss of endoglin expression alone does not result in the transformation of the nontumorigenic MCF10A cells. Immunoblotting of MCF10A cells stably infected with different shRNA lentiviral constructs against endoglin (shEng) or control (shCont). Note, the shEng2 cell line showed negligible endoglin knockdown and therefore was used as an independent shRNA control. (c) MCF10A cell lines stably expressing control shRNA (shCont, shEng2) or endoglin knockdown (shEng1, shEng5) shRNA constructs were grown in 3D culture and fixed on day 20. Cells were permeabilized and stained for collagen IV and Alexa488 anti-rabbit Ig (green), the Golgi protein b-COP and Alexa555 anti-rat Ig (red) and DAPI (blue). Left panel, representative confocal images. Scale bar, 25 mm. Right panel, mean % of abnormal acini morphology for three independent experiments±s.e.m.
We next tested whether endoglin might function to modulate the effects of activated oncogenes. For this, we employed MCF10A cells ectopically expressing a chimeric ErbB2 fusion protein (MCF10A.ErbB2). In these MCF10A.ErbB2 cells, addition of the AP1510 dimerizer activates ErbB2 signaling (Muthuswamy et al., 2001) and can be used to delineate the molecular events that cooperate with oncogenes during tumor progression (Seton-Rogers et al., 2004; Aranda et al., 2006) . MCF10A.ErbB2 cells were infected with endoglin or shCont lentiviruses and again substantial knockdown was achieved with shEng1 and shEng5, but only minimal knockdown was achieved with shEng2 ( Figure 2a ). In the control cell lines (parental, shCont, shEng2) addition of the AP1510 dimerizer for the last 24 h of the 5-day culture resulted in an increased number of acini invading into the Matrigel containing 3D matrix. Despite no significant effect of exogenously added TGF-b1, this increase was abrogated by the addition of the TGF-b receptor inhibitor SB431542 (Figure 2b ), which is consistent with the presence of TGF-b in Matrigel (see Materials and methods). In the endoglin knockdown lines (shEng1 and shEng5), AP1510-treated cultures produced acini with significantly more protrusions that invaded through the basement membrane compared with shCont cell lines (shEng1, P ¼ 0.0403; shEng5, P ¼ 0.0126). These endoglin knockdown lines also produced more invasive acini in the absence of AP1510, which probably reflects leaky activation of the ErbB2 fusion protein (Seton-Rogers et al., 2004) . Again, the number of invasive acini was significantly reduced in the presence of the SB43152 inhibitor (shEng1, P ¼ 0.0087; shEng5, P ¼ 0.0428). In long-term culture (day 20), the acini from the shEngknockdown lines (shEng1, shEng5) were more motile and invasive than those from the shCont or parental lines, and coalesced to form larger, more disorganized and multiacinar structures (Supplementary Figure 2) . In both the MCF10A and MCF10A.ErbB2 lines, downregulation of endoglin expression had no effect on cell proliferation in the presence or absence of TGF-b (Supplementary Figure 3) . Together these data demonstrate that endoglin serves to limit the pro-invasive effects of ErbB2 activation in non-tumorigenic breast cells and suggest that in the context of an activated oncogene, endoglin acts as breast cancer suppressor. ErbB2 shCont and shEng5 cell lines were starved overnight and treated with 5 ng/ml TGF-b1 (MCF10A) or 5 ng/ml TGF-b1 plus 1 mM AP1510 dimerizer (MCF10A.ErbB2) for 0-24 h. Cells were lysed in reducing sample buffer, total protein lysate resolved by 10% SDS-PAGE and subject to immunoblotting with the indicated antibodies. Molecular size markers are in kDa. (b, d) MCF10A or MCF10A.ErbB2 shCont and shEng5 cell lines were starved overnight and treated±5 ng/ml TGF-b1 (MCF10A) or 1 mM AP1510 ± 5 ng/ml TGF-b1 (MCF10A.ErbB2) for 3 h. Cells were lysed and total RNA extracted. cDNA was synthesized and subject to qPCR with Taqman probes specific for SNAI2, PAI1 and ANGPTL4. Data shown is the mean ± s.e.m. of RQ relative expression from three independent experiments.
be noted that in comparison with the data shown in Figure 2b , cells were serum starved overnight to ensure basal levels of TGF-b signaling at time 0. In both cell lines, endoglin downregulation had no effect on TGF-b induced Smad2/3 or Smad1/5/8 phosphorylation. Similarly, endoglin downregulation had no effect on the transcriptional upregulation of the TGF-b responsive genes SNAI2, ANGPTL4 and PAI1. These data also demonstrate that addition of AP1510 dimerizer to the MCF10A.ErbB2 cells in the absence of TGF-b does not stimulate Smad activation or transcription of TGF-bresponsive genes. Alternative non-Smad signaling, particularly signaling to the cytoskeleton, has been shown to have an important role in the pro-invasive effects of TGF-b (Moustakas and Heldin, 2005; Zhang, 2009) . To investigate the effect of endoglin on cytoskeletal regulation, MCF10A and MCF10A.ErbB2 cells were subject to scratch-wound migration assays ( Figure 4 ). The MCF10A cell migration was modestly inhibited by TGF-b and this inhibition was not relieved by endoglin downregulation (Figure 4a ). In endothelial cells and myoblasts, it has been reported that endoglin suppresses TGF-b-mediated ERK1/2 activation (Rodriguez-Barbero et al., 2006; Lee and Blobe, 2007) . In these MCF10A epithelial cells, endoglin downregulation had no effect on the duration or extent of TGF-b-induced ERK1/2 activation ( Figure 3a ). In the MCF10A.ErbB2 cells, activation of ErbB2 with the AP1510 dimerizer alone did not promote cell migration (Figure 4a , bars 1 and 5), but downregulation of endoglin in cooperation with ErbB2 activation significantly increased cell motility (P ¼ 0.0255; Figure 4a , compare bars 3, 5 and 7). Consistent with previous reports, ( Seton-Rogers et al., 2004) , we also observed that activation of ErbB2 renders MCF10A cells responsive to the pro-migratory effects of exogenously added TGF-b1. Confocal microscopy analysis of the wounded AP1510-treated MCF10A.Erb2 cell monolayers revealed that shCont transfected cells had very few focal adhesions and a thick layer of actin filaments parallel to the wound edge, consistent with the inability of these cells to actively migrate into the wound (Figure 4b ). In contrast, the actively migrating shEng5 cells formed numerous small vinculin-positive focal adhesions and actin protrusions. Consistent with the cell migration data (Figure 4a) , treatment of MCF10A.ErbB2 shCont cells with TGF-b1 resulted in an increased number of focal adhesions. However, these were notably larger in size than those found in the TGFb-treated shEng5 knockdown cells. It is well established that larger focal adhesions are more mature, longerlived structures resulting from reduced focal adhesion turnover and that this in turn leads to less efficient cell migration (Webb et al., 2002) . Together these data support a role for endoglin in attenuating activated ErbB2-promoted cell migration through effects on the focal adhesions and the actin cytoskeleton.
Endoglin inhibits cell invasion and metastatic colonization in vivo. To validate a functional role for endoglin in an independent cell system and investigate directly the role (Figure 5e ) of the 231-VEC cells as monitored by scratch-wound assays and Matrigel-coated transwell invasion assays, respectively, and this induction was blocked with the TGF-b receptor inhibitor, SB431542. Interestingly, ectopic expression of endoglin reduced both the basal level of migration and invasion, and suppressed the ability of TGF-b1 to enhance these processes in the MDA-MB-231 cells (Figures 5d and e) .
To assess the relevance of these findings to cells in vivo, metastatic colonization assays were undertaken by inoculating the cells through the tail vein into immunocompromised mice. 231-ENG cells produced significantly less lung nodules than 231-VEC cells (Figure 6a) . Recently, TGF-b activity has been shown to increase the extravasation of breast cancer cells into the lung parenchyma (Padua et al., 2008) . To investigate this aspect of the metastatic cascade, the 231-VEC and 231-ENG cell lines were infected with a luciferaseexpressing lentivirus to generate the 231-VEC(Luc) and 231-ENG(Luc) lines. Following tail vein inoculation, In Vivo Imaging Systems (IVIS) bioluminescent imaging was used to monitor the short-term retention of these cells in the lung (Figure 6b ) At 24 h, IVIS imaging demonstrated a significantly higher proportion of 231-VEC(Luc) cells compared with 231-ENG(Luc) cells retained in the lung, which at later times (5 weeks) gave rise to a higher metastatic burden.
Endoglin expression in breast tumors correlates with improved clinical outcome. To relate these findings to clinical samples, endoglin expression was examined in a large cohort of invasive breast cancers using the 4G11 anti-endoglin antibody (see Supplementary Figure 6 for antibody validation). In all, 20.6% (45/218) of the samples had endoglin-positive tumor cells (Figure 7a ; Supplementary Table 1) . As expected, endoglin was also expressed at high levels in the tumor vasculature providing an internal control for immunohistochemical scoring. Additional immunohistochemistry with an alternative anti-endoglin antibody (SN6h) independently validated the specificity of the tumor cell staining (data not shown). Analysis of the clinicopathological parameters revealed that endoglin expression in the tumor cells was significantly correlated with histological grade three (P ¼ 0.0028) and estrogen receptor (ER)-negative (P ¼ 0.0023) tumors (Supplementary Table 1 ). This cohort of patients was uniformly treated with adjuvant anthracycline-based chemotherapy plus tamoxifen for those with ER-positive tumors. Endoglin expression in the tumor cells was significantly associated with improved metastasis-free (P ¼ 0.0241) and overall (P ¼ 0.0245) survival (Figure 7b) . Similarly, within the subgroup of more aggressive ER-negative breast cancers, expression of endoglin in the tumor cells showed a significant correlation with improved metastasis-free (P ¼ 0.0175) and overall (P ¼ 0.0251) survival (Supplementary Figure 7 ). These observations demonstrate that endoglin is expressed in the tumor cells of a subset of breast carcinomas and that this expression correlates with improved patient prognosis.
Regulation of endoglin expression by ENG methylation.
In our preliminary studies, we identified ENG as a candidate gene for epigenetic regulation in breast cancer cell lines. The ENG gene contains a small CpG island in exon-1 (Figure 8 ). To examine whether this island is indeed methylated in breast cancer cell lines, genomic DNA was subject to methylation-specific PCR (MSP) (Figure 8a ) and bisulfite sequencing (Figure 8b) . A high level of methylation was detected in all endoglinnegative breast cancer lines (see Figure 1a) . Moreover, treatment with a demethylating agent reversed this transcriptional inhibition (Figure 8c ). To investigate whether ENG methylation is a mechanism for regulating expression in tumors, genomic DNA isolated from an independent cohort of snap-frozen primary breast cancers was subject to MSP analysis (Figure 8d ). In all, 23.3% (30/129) of the tumors were endoglin-positive and again this significantly correlated with ER negativity and with high tumor grade (data not shown). MSP analysis revealed that 17.1% (22/129) of the tumors were methylated and there was a significant inverse correlation between the ENG methylation status and endoglin expression (P ¼ 0.0250). The MSP data from the clinical samples was validated by bisulfite sequencing a subset of the tumors scored as methylated or unmethylated by MSP (Figure 8e ). Finally, genomic DNA was also isolated from fresh frozen normal breast tissue samples and from microdissected epithelial regions from paraffin-embedded normal breast tissue samples. MSP analysis confirmed the absence of ENG methylation in all the normal breast samples (Supplementary Figure 8) . These data demonstrate that ENG methylation is a significant mechanism preventing endoglin expression and is acquired in some breast tumors during cancer progression.
Discussion
In this study we show that endoglin functions in breast cancer cells to inhibit cell migration and invasion in vitro and metastatic colonization in vivo. The clinical relevance of these findings was verified by surveying a large cohort of invasive breast cancers and demonstrating that endoglin expression in the tumor cell compartment significantly correlates with improved clinical outcome. Further, we demonstrated by MSP analysis and bisulfite sequencing that endoglin expression in breast cancers and cancer cell lines is epigenetically regulated by gene methylation. This latter finding extends previous work in which MSP analysis was used to demonstrate ENG CpG island methylation in esophageal cell lines and two esophageal tumors (Wong et al., 2008) and indicates that this mechanism of ENG gene regulation may be utilized in multiple cancer types. Of interest, reduced endoglin expression enhances malignant progression in a mouse model of skin carcinogenesis (Quintanilla et al., 2003) ; however, the mode of endoglin downregulation is by shedding of the extracellular domain (Perez-Gomez et al., 2007) . As the mouse Eng gene does not contain a CpG island this may reflect an alternative mechanism to regulate mouse Eng expression. Finally, in our study it was also noted that not all endoglin-positive breast cancers showed ENG methylation. The reason for this is that we may be underestimating the level of ENG methylation as our analysis was conducted on whole-tumor lysates, which will contain ENG-unmethylated stromal cells and normal epithelial cells (see Materials and methods). In addition, it has been proposed that the methylation of CpG islands only occurs at gene promoters that have already been transcriptionally silenced and that methylation functions to maintain the silenced state (Illingworth and Bird, 2009) . Hence, in breast tumors, methylation of the ENG CpG island may be a secondary event after transcriptional silencing of the gene promoter.
A key aspect of our studies was to demonstrate that endoglin downregulation alone is insufficient to transform (Figure 1c ) or enhance the migration (Figure 4 ) of non-tumorigenic MCF10A breast epithelial cells but is required to reveal the full migratory/invasive phenotype following ErbB2 oncogenic activation (Figure 2b ; Figure 4 ). The MDA-MB-231 cell line has activating K-Ras and B-Raf mutations (Ikediobi et al., 2006) and like the activated MCF10A.ErbB2 cell line is responsive to the pro-migratory and pro-invasive effects of TGF-b ( Figure 5) . In both the MCF10A.ErbB2 and MDA-MB-231 cells, expression of endoglin attenuates the promigratory/invasive activities of TGF-b but has no effect on TGF-b-mediated Smad2/3 or Smad1/5/8 signaling. Previously it has been reported that endoglin can inhibit TGF-b-mediated migration and invasion of prostate-cancer cell lines (Craft et al., 2007; Romero et al., 2010) and transformed mouse keratinocytes (Perez-Gomez et al., 2007) . Consistent with our findings, endoglin had no effect on TGF-b-mediated Smad activation in the prostate cancer cells. In contrast, in mouse keratinocytes endoglin downregulation enhanced TGF-b-mediated Smad2/3 phosphorylation. The reasons for these differing effects on TGF-b signaling are not known but may reflect differing mechanisms regulating the interplay between endoglin and TGF-b in squamous carcinomas versus prostate/breast carcinomas. Surprisingly, a pro-invasive role for endoglin has been reported recently in MDA-MB-231 cells in vitro (Oxmann et al., 2008) , which is in direct contrast to the in vitro and in vivo findings reported here. However, it should be noted that these authors performed their scratch-wound migration and Boyden-chamber invasion assays over a 3-h period and therefore may be monitoring a short-term cellular phenotype rather than cell migration/invasion.
Our data clearly show that endoglin attenuates the pro-migratory and pro-invasive effects of TGF-b1 in cells containing active oncogenes (MCF10A.ErbB2, MDA-MB-231), but that in these cells endoglin does not modulate TGF-b-induced Smad signaling. In addition, it is notable that in the absence of exogenously added TGF-b1 endoglin reduces the basal migration and invasion of these breast cell lines. Mechanistically this indicates that in epithelial cells endoglin has both TGF-b-dependent and independent functions. The current literature suggests two potential mechanisms by which the TGF-b-independent effects may be mediated. First, endoglin shares sequence similarity with the other TGF-b co-receptor betaglycan (also known as TGF-b receptor III). Betaglycan can also inhibit cell migration independently of TGF-b and its receptors, and instead associates directly with b-arrestin (Mythreye and Blobe, 2009 ). Here we observed that endoglin expression modulates focal adhesion formation and turnover. This is consistent with the previous data in endothelial cells where endoglin has been shown to bind directly to zyxin and to sequester zyxin and its binding partners p130cas and CrkII away from focal adhesion complexes (Conley et al., 2004) . In addition, endoglin has been shown to interact with zyxin-related protein 1 resulting in a dramatic change in the structure of the actin cytoskeleton and the localization of zyxinrelated protein 1 (Sanz-Rodriguez et al., 2004) . Second, in addition to TGF-b1, endoglin can bind, in association with different TGF-b superfamily receptors, to BMP2, BMP7, BMP9, activin A and TGF-b3 (Cheifetz et al., 1992; Barbara et al., 1999; Scharpfenecker et al., 2007) , and has been reported to have a functional role in modulating responses to BMP2 (Ishibashi et al., 2010) and BMP7 (Scherner et al., 2007) in periodontal ligament cells and myoblasts, respectively. Although there are no published reports of endoglin modulating the response to other TGF-b family ligands in epithelial cells, it will be of interest in the future to determine whether the TGF-b1-independent functions of endoglin expressed on tumor cells may be mediated by binding to alternate ligands and/ or other TGF-b superfamily receptors.
Materials and methods
Cells and reagents MCF10A.ErbB2 cells were obtained from Senthil Muthuswamy (Princess Margaret Hospital, Toronto, ON, Canada). All other cell lines were obtained from ATCC (Manassas, VA, USA). MDA-MB-231 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum and, when applicable, starved overnight in serum-free DMEM. MCF10A and MCF10A.ErbB2 cells were cultured, DMEM:F12 (1:1) with 5% donor horse serum, insulin (10 mg/ ml), epidermal growth factor (EGF) (20 ng/ml), hydrocortisone (0.5 mg/ml) and cholera toxin (100 ng/ml) as previously described (Muthuswamy et al., 2001) and, when applicable, starved overnight in assay media containing 1% donor horse serum and no EGF.
For shRNA downregulation, MCF10A and MCF10A. ErbB2 cells were infected with Mission lentiviral particles (Sigma, St Louis, MO, USA) according to the manufacturer's instructions. Individual infections were performed with five different human endoglin shRNA constructs (SHVRSC-TRCN0000083138 to SHVRSC-TRCN0000083142) or with a non-targeting shCont construct (SHVRSC-TRCN0000098116) at a multiplicity of infection of 10. All five shEng constructs target both large-and short-endoglin isoforms. For ectopic endoglin expression, MDA-MB-231 cells were transfected with pcDNA3.1 alone (231-VEC) or pcDNA3.1 containing human long-endoglin isoform cDNA (231-ENG). 231-ENG cells were FACSorted using the anti-endoglin mAb SN6h to enrich for an endoglin-positive population. The qPCR analysis demonstrated that expression of endoglin in the 231-ENG cells was equivalent to the expression in the endogenously expressing MCF10A and SKBR3 cells. To generate the luciferase-expressing 231-VEC(Luc) and 231-ENG(Luc) lines, 231-VEC and 231-ENG cells were infected with pGF1-CMV (System Biosciences, Mountain View, CA, USA) lentiviral particles.
As indicated, cells were treated with 5 ng/ml human TGF-b1 (R&D Systems, Minneapolis, MN, USA), 20 mM TGF-breceptor inhibitor SB431542 (Tocris), 5 ng/ml EGF and/or 1 mM AP1510 dimerizer (Ariad Pharmaceuticals, Cambridge, MA, USA). Antibodies were obtained as follows: human endoglin mAb (4G11, Novocastra, Newcastle Upon Tyne, UK; and SN6h, Dako, Ely, Cambridgeshire, UK); a-tubulin (Sigma); rabbit polyclonal ERK1/2 (gift from CJ Marshall); collagen IV (Acris, Herford, Germany); laminin V (Chemicon, Watford, UK); b-COP (23C, ICR Hybridoma Unit); vinculin (Sigma); Smad2/3 (BD Biosciences, Oxford, UK), p-Smad2, pSmad3 and pSmad1/5/8 (Cell Signaling, Danvers, MA, USA); Smad1 (Chemicon); AlexaFluor secondary antibodies and phalloidin conjugates (Invitrogen, Paisley, Scotland).
Cell assays
For migration assays, confluent cells in a 12-well plate were scratched with a P1000 pipette tip and wound closure monitored on a time-lapse microscope for 16-21 h. For invasion assays, cells were starved overnight and 2.5 Â 10 4 cells were plated onto Matrigel invasion chambers (BD Biosciences) with a lower well containing DMEM plus 10% fetal bovine serum ± TGF-b1 or SB431542. After 24 h, transmigrated cells on the underside of the filter were fixed in methanol and stained with 1% toluidine blue/ 1% borax. Three fields of view were taken of each insert at Â 5 magnification and cells counted using ImageJ software. Each condition was performed in triplicate. For 3D acini culture, MCF10A and MCF10A.ErbB2 cells were cultured as previously described (Muthuswamy et al., 2001 ) on 100% growth factorreduced Matrigel (BD Biosciences) or a 1:1 mixture of Matrigel and collagen I (Purecol, Leimuiden, The Netherlands), respectively. The growth factor-reduced Matrigel contains 1.7 ng/ml TGF-b. For immunofluorescence staining, cells or acini were fixed with 4% paraformaldehyde for 40 min, permeabilized in 0.1% Triton X-100 for 10 min and stained with primary antibody for 1 h at room temperature or overnight at 4 1C, followed by AlexaFluor-conjugated secondary antibody. Cells or acini were counterstained with Alexa546-phalloidin and 4 0 ,6-diamidino-2-phenylindole (DAPI). Fluorescent images were captured sequentially in three channels on a Leica Microsystems TCS-SP2 confocal microscope (see Supplementary Methods for image acquisition details).
qPCR qPCR was performed as previously described (Klingbeil et al., 2010) . Briefly, qPCR primers were purchased as assayson-demand from Applied Biosystems (Warrington, UK): Hs00164438_m1 for human ENG, Hs00161904_m1 for human SNAI2, Hs01101127_m1 for human ANGPTL4, Hs00167155_m1 for human SERPINE1 and 4310884E for glyceraldehyde-3-phosphate dehydrogenase. qPCR was performed on 0.5 ml cDNA using Taqman gene-expression assays on an ABI Prism 7900HT sequence detection system (Applied Biosystems). Each reaction was performed in triplicate. Data were analyzed with the Applied Biosystems SDS 2.2.1 software using glyceraldehyde-3-phosphate dehydrogenase for normalization. Fold change is represented by relative quantification units.
Lung colonization assay A total of 2 Â 10 6 cells were injected into the tail vein of 6-week athymic female mice (Ncr-nude). Luciferase bioluminescence was measured using an IVIS 100 (Caliper, Runcorn, UK). Lungs were excised from the mice at necropsy and surface nodules counted. Mice were allowed food and water ad libitum. All procedures were in accordance with UK Home Office legislation.
Clinical samples
The tissue microarray consisted of replicate 0.6 mm cores of 245 invasive breast carcinomas from patients diagnosed and managed at the Royal Marsden Hospital. All patients were primarily treated with surgery, followed by anthracycline-based chemotherapy and endocrine therapy for patients with ER-positive tumors. Follow-up was for 0.5-125 months (median ¼ 67 months, mean ¼ 67 months). Clinicopathological features are shown in Supplementary Table 1. The study was approved by the Royal Marsden NHS Foundation Trust Ethics Committee. An independent series of previously untreated breast cancers from the Tayside Tissue Bank were provided as a tissue microarray and as snap-frozen tumors. Genomic DNA was extracted from the frozen material using the M48 DNA extraction robot (Qiagen, Crawley, West Sussex, UK) following histopatholo-gical review to ensure over 30% representation of neoplastic cells. The study was approved by the Tayside Tissue Bank review committee (under delegated authority from the Local Regional Ethics Committee).
Immunohistochemistry
For immunohistochemical staining, 3 mm thick sections were dewaxed in xylene, taken through ethanol (99.7-100%, v/v), and subjected to high-temperature antigen retrieval (2 min of pressure cooking) in target-retrieval citrate buffer (pH 6; Dako). Slides were allowed to cool for 20 min at room temperature, incubated with an avidin/biotin block (Vector Laboratories, Peterborough, UK) and then incubated with anti-endoglin mAb 4G11 (1:100) for 1 h at room temperature. Detection was performed with the VectaStain ABC system (Vector Laboratories). Positive and negative (omission of the primary antibody and substitution with IgG-matched control) controls were included in each slide run. Expression of endoglin was scored as positive if greater than 10% of the tumor cells were positive. Immunohistochemical analysis was performed by two observers (LH and JRF) blinded to the results of other immunohistochemical markers and patients' outcome.
Methylation analysis
Genomic DNA (gDNA) was extracted from cell pellets and tumor samples using the DNAeasy kit (Qiagen) and subject to bisulfite modification with the Zymo EZ DNA Methylation kit (Genetix, New Milton, Hampshie, UK). Details of primers, MSP conditions and sequence analysis are provided in the Supplementary Methods.
Statistical analyses
All in vitro cell experiments were analyzed with a two-tailed Student's t-test with a CI of 95%. Analysis of the lung metastasis experiments was performed using the two-tailed Mann-Whitney U-test. Categorical comparisons were performed with a two-tailed Fisher's exact test. Metastasis-free survival was expressed as the number of months from diagnosis to the occurrence of distant relapse. Overall survival (breast cancer-specific survival) was expressed as the number of months from diagnosis to the occurrence of an event (disease-related death). Cumulative survival probabilities were calculated using the Kaplan-Meier method. Differences between survival rates were tested with the Log-Rank test.
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